VTRS: Viatris Inc. Stock

by  •  • Comments Off on VTRS: Viatris Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 9,107.85
Enterprise Value ($M) 22,420.25
Book Value ($M) 18,635.50
Book Value / Share 15.61
Price / Book 0.49
NCAV ($M) -13,344.70
NCAV / Share -11.18
Price / NCAV -0.68

Profitability (mra)
Return on Invested Capital (ROIC) -0.02
Return on Assets (ROA) -0.01
Return on Equity (ROE) -0.03

Liquidity (mrq)
Quick Ratio 0.98
Current Ratio 1.65

Balance Sheet (mrq) ($M)
Current Assets 9,520.70
Assets 41,500.90
Liabilities 22,865.40
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 14,739.30
Operating Income 1,409.10
Net Income -634.20
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 2,302.90
Cash from Investing 1,800.70
Cash from Financing -4,330.40

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-24 13G Davis Selected Advisers 5.90 -0.12

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   For the Fiscal Year Ended December 31, 2023 OR ☐ Transition

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-15 1,784,972 9,301,790 19.19
2025-04-14 2,324,270 10,665,283 21.79
2025-04-11 1,976,102 14,143,494 13.97
2025-04-10 2,570,652 18,384,803 13.98

(click for more detail)

Similar Companies
VIR – Vir Biotechnology, Inc. VOR – Vor Biopharma Inc.
VRTX – Vertex Pharmaceuticals Incorporated VTYX – Ventyx Biosciences, Inc.
VYGR – Voyager Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io